Acutus Medical Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

44.8%

Wachstumsrate der Gewinne

103.0%

EPS-Wachstumsrate

Medical Equipment Wachstum der Industrie	8.9%
Wachstumsrate der Einnahmen	-39.2%
Eigenkapitalrendite	n/a
Netto-Marge	-101.6%
Letzte Ertragsaktualisierung	31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Investors Give Acutus Medical, Inc. (NASDAQ:AFIB) Shares A 29% Hiding

Feb 24

Market Cool On Acutus Medical, Inc.'s (NASDAQ:AFIB) Revenues Pushing Shares 43% Lower

Dec 20

Take Care Before Diving Into The Deep End On Acutus Medical, Inc. (NASDAQ:AFIB)

Jul 18

Acutus files for FDA approval of catheter ablation system AcQBlate

Oct 18

Acutus Medical Non-GAAP EPS of -$0.93 misses by $0.17, revenue of $4.1M beats by $0.13M

Aug 11

Acutus Medical sees Q2 revenue above consensus estimate

Jul 21

Acutus Medical, Inc. (NASDAQ:AFIB) Analysts Just Trimmed Their Revenue Forecasts By 25%

Apr 06

Analysts Have Been Trimming Their Acutus Medical, Inc. (NASDAQ:AFIB) Price Target After Its Latest Report

May 15

Aufschlüsselung der Einnahmen und Ausgaben

Wie Acutus Medical Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

OTCPK:AFIB Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Mar 24	10	-10	13	3
31 Dec 23	7	-12	14	3
30 Sep 23	3	48	3	-6
30 Jun 23	2	41	6	-5
31 Mar 23	1	63	10	-4
31 Dec 22	3	29	20	3
30 Sep 22	16	-86	54	31
30 Jun 22	17	-94	60	34
31 Mar 22	17	-127	62	35
31 Dec 21	17	-118	64	37
30 Sep 21	15	-116	63	37
30 Jun 21	14	-119	63	36
31 Mar 21	10	-113	56	35
31 Dec 20	8	-102	50	33
30 Sep 20	7	-92	43	32
30 Jun 20	4	-93	35	30
31 Mar 20	4	-100	33	27
31 Dec 19	3	-97	27	23
31 Dec 18	2	-48	13	19

Wachsende Gewinnspanne: AFIB ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: AFIB ist unrentabel, hat aber in den letzten 5 Jahren die Verluste mit einer Rate von 44.8% pro Jahr reduziert.

Acutus Medical Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Full year 2023 earnings released: US$0.41 loss per share (vs US$1.40 loss in FY 2022)

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.72 loss in 3Q 2022)

Acutus Medical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. to Report Q2, 2023 Results on Aug 07, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Nasdaq Files A Form 25 Notification of Delisting with the Securities and Exchange Commission to Complete Acutus Medical, Inc.'s Delisting

Acutus Medical, Inc.(NasdaqCM:AFIB) dropped from NASDAQ Composite Index

Acutus Medical Provides Non-Compliance Update

Acutus Medical, Inc., Annual General Meeting, Jun 13, 2024

New minor risk - Shareholder dilution

New major risk - Negative shareholders equity

Full year 2023 earnings released: US$0.41 loss per share (vs US$1.40 loss in FY 2022)

Investors Give Acutus Medical, Inc. (NASDAQ:AFIB) Shares A 29% Hiding

Acutus Medical, Inc. Announces Board Changes

Market Cool On Acutus Medical, Inc.'s (NASDAQ:AFIB) Revenues Pushing Shares 43% Lower

Acutus Medical, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.72 loss in 3Q 2022)

Acutus Medical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Acutus Medical Receives A Letter from Nasdaq Approving the Company’s Application to List Its Securities on the Nasdaq Capital Market

Acutus Medical, Inc. Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Take Care Before Diving Into The Deep End On Acutus Medical, Inc. (NASDAQ:AFIB)

Acutus Medical, Inc. Announces Executive Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. Provides Revenue Guidance for the Year 2023

Acutus Medical Receives Notice from the Nasdaq Regarding Not in Compliance with Listing Rule 5450(a)(1)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. Announces Results from the AcQForce Flutter Study “AcQForce Flutter: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter”

Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Price target increased to US$4.13

Acutus Medical Achieves Eu Mdr Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic

Acutus Medical, Inc. Announces Full Market Release of Next Generation Software Platform AcQMap 8.5

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations

Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Acutus Medical Receives Non-Compliance Notice From Nasdaq

High number of new directors

Acutus Medical, Inc. Announces Submission of Premarket Approval Application for AcQBlate Force Sensing Ablation Catheter & System

Acutus files for FDA approval of catheter ablation system AcQBlate

Glancy Prongay & Murray LLP Appoints Lead Counsel in Securities Class Action Against Acutus Medical, Inc

Acutus Medical, Inc. Announces Board Changes

Consensus forecasts updated

Price target increased to US$3.38

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Acutus Medical Non-GAAP EPS of -$0.93 misses by $0.17, revenue of $4.1M beats by $0.13M

Acutus Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Acutus Medical Announces Approval of its AcQMap System and AcQMap 3D Imaging and Mapping Catheter in Japan

Acutus Medical, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Acutus Medical sees Q2 revenue above consensus estimate

Acutus Medical, Inc. announced that it has received funding from Deerfield Management Company, L.P. Series C

Medtronic plc (NYSE:MDT) completed the acquisition of Left-heart Access Portfolio from Acutus Medical, Inc. (NasdaqGS:AFIB).

Acutus Medical, Inc. Announces FDA Clearance, Commercial Launch of AcQCross Line Extension Compatible with Watchman Delivery System

Acutus Medical Receives Non-Compliance Notice from Nasdaq

Consensus forecasts updated

Acutus Medical, Inc. Completes Enrollment in Ide Trial with Its Acqblate® Force Sensing Ablation System

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$3.50

High number of new directors

Price target decreased to US$4.00

Acutus Medical, Inc. (NASDAQ:AFIB) Analysts Just Trimmed Their Revenue Forecasts By 25%

Consensus revenue estimates fall by 25%

Full year 2021 earnings: EPS exceeds analyst expectations

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Acutus Medical, Inc

Acutus Medical, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Independent Director recently bought US$151k worth of stock

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$1.95 loss in 3Q 2020)

Price target decreased to US$16.40

Acutus Medical: A Name To Slowly Accumulate

Acutus Medical, Inc. Provides Revenue Guidance for the Year 2021

Second quarter 2021 earnings released: US$1.02 loss per share (vs US$32.24 loss in 2Q 2020)

AcQMap 8, Acutus Medical’s Innovative Suite of Software Upgrades, Receives FDA Clearance and CE Mark

Acutus Medical, Inc.: Paradigm-Shifting Technology At A Shocking Price

Acutus Medical, Inc. has completed a Follow-on Equity Offering in the amount of $77 million.